Nath Bio-Genes (India) Limited - agriculture in Aurangabad, Maharashtra, India. FY 2026 financials & compliance.
CIN L01110MH1993PLC072842 Incorporated 14 July 1993 ROC Mumbai HQ Aurangabad, Maharashtra, India
Active Listed - NSE: NATHBIOGEN · BSE: 537291 Public Limited Company agriculture
Data last updated
Market Cap
₹252 Cr
NATHBIOGEN · NSE
Share Price
₹131.01
-1.03% today
Revenue
₹445 Cr
FY 2025-26 · +22.0% YoY
EBITDA
₹52.44 Cr
Margin 11.8%
Net Profit
₹36.24 Cr
FY 2025-26 · -7.2% YoY
P/E (TTM)
7.5x
P/B 0.4x
Authorised capital
₹21 Cr
Registered with MCA
Paid-up capital
₹19 Cr
Issued & subscribed

About Nath Bio-Genes (India) Limited

Data last updated:

Nath Bio-Genes (India) Limited is a public limited company based in Aurangabad, Maharashtra, India. It operates in the seed production and distribution segment of the agriculture sector. It was incorporated on 14 July 1993 and has been in existence for over 33 years.

The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L01110MH1993PLC072842. Its GSTIN is 03AABCN7978E1ZD (Punjab). The company holds 15 GST registrations, of which 13 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 537291 and NSE: NATHBIOGEN.

The company has an authorised share capital of ₹21 Cr and a paid-up capital of ₹19 Cr. It is led by directors including Satish Laxminarayan Kagliwal (Managing Director) and Madhukar Dhondiraj Deshpande.

Its last annual general meeting (AGM) was held on 22 August 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Nath House Nath Road, Aurangabad, Maharashtra, India – 431005.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹445.1 Cr, a growth of 22% compared to the previous year. For the same year it recorded a net profit of ₹36.24 Cr (net margin 8.1%) and EBITDA of ₹52.44 Cr (EBITDA margin 11.8%). The net worth stands at ₹680.45 Cr (up 5.6% YoY). Total assets are valued at ₹823.91 Cr (up 6.9% YoY).

The company has about 417 employees on its provident fund (EPFO) records.

The company is associated with 1 brand: Nath Bio-Genes. As per MCA filings, the company has open charges of ₹114.1 Cr and satisfied charges of ₹183.2 Cr on record. Court records list 34 cases involving the company, including 18 filed by the company and 16 filed against it; 14 cases are pending. The company has 44 deals on record (43 market trades, 1 qip); the latest was in September 2025.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website nathbiogenes.com.

Company details

CIN L01110MH1993PLC072842
Registration Number 072842
Incorporation Date 14 July 1993
ROC Mumbai
Listing Status Listed - Listed on NSE (NATHBIOGEN); Listed on BSE (537291)
Company Status Active
Date of Last AGM 22 August 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant

CIN history

Nath Bio-Genes (India) has one previous CIN (Corporate Identification Number): U01110MH1993PLC072842. The current CIN is L01110MH1993PLC072842, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L01110MH1993PLC072842Current
U01110MH1993PLC072842Previous

Contact details

Nath Bio-Genes (India) Limited's registered office is in Aurangabad, Maharashtra. Its website is nathbiogenes.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Social Media
  • Registered Address
    Nath House Nath Road, Aurangabad, Maharashtra, India – 431005
  • Industry
    Agriculture, Seed Production & Distribution

To see the full contact details of Nath Bio-Genes (India) Limited, buy the company report.

Comprehensive company report
Nath Bio-Genes (India) Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Nath Bio-Genes (India) operates one associated brand: Nath Bio-Genes. Each brand links to its own profile.

BrandDescriptionWebsite
Company that develops, produces, and markets hybrid and seeds for various crops, with a focus on improving crop yieldsnathbiogenes.com

Business activity

The main business activity of Nath Bio-Genes (India) is agriculture, forestry, fishing. In detail, this covers support activities to agriculture and other activities including hunting.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
AAgriculture, forestry, fishingA4Support activities to agriculture and Other Activities including hunting

To see the full business activity and turnover split of Nath Bio-Genes (India) Limited, buy the company report.

Financials of Nath Bio-Genes (India) Limited

FY 2025-26 filings available

Nath Bio-Genes (India) Limited reported revenue of ₹445.1 Cr (up 22% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹445 Cr
+22.0% YoY
EBITDA
₹52.44 Cr
+5.0% YoY
Profit After Tax
₹36.24 Cr
-7.2% YoY
Net Worth
₹680 Cr
+5.6% YoY
Total Assets
₹824 Cr
+6.9% YoY
Total Debt
₹138 Cr
+13.1% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2012-13
Income statement
Revenue445365333301278138
Revenue growth+22.0%+9.7%+10.4%+8.3%--
EBITDA52.4449.9649.9548.83(51.56)19.90
EBITDA margin+11.8%+13.7%+15.0%+16.2%-18.5%+14.5%
Profit before tax46.3140.5841.5736.16(63.43)12.30
Net profit36.2439.0736.3335.0323.7411.75
Net profit margin+8.1%+10.7%+10.9%+11.6%+8.5%+8.5%
EPS (₹)20.9820.3120.8518.43(35.46)7.34
Balance sheet
Total assets82477072368163778.13
Net worth68064461057354257.47
Total debt13812311010592.9519.19
Cash & bank76.0088.9077.4138.004.182.48
Net working capital50543441540936639.60
Cash flow
Cash from operations(12.57)17.5874.5938.3717.05-
Cash from investing3.46(3.96)(27.40)(2.88)(19.85)-
Cash from financing(3.79)(2.13)(7.78)(1.67)(22.23)-
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue32851.5965.9643.8528451.9736.8732.19
Revenue growth (YoY)+15.8%-0.7%+78.9%+36.2%+16.3%---
Other income3.103.634.424.003.834.400.480.08
EBITDA35.154.473.576.1029.280.428.034.81
EBITDA margin+10.7%+8.7%+5.4%+13.9%+10.3%+0.8%+21.8%+14.9%
Depreciation1.011.030.980.990.981.340.830.83
Interest4.264.594.543.663.201.373.902.98
Profit before tax32.982.482.475.4528.932.113.781.08
Tax0.722.500.870.640.660.631.14(0.03)
Net profit32.26(0.02)1.604.8128.271.482.641.11
EPS (₹)16.98(0.79)0.892.5314.880.421.330.53
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue432362333301278308280
Revenue growth+19.1%+8.9%+10.4%+8.2%-9.5%+9.9%-
EBITDA52.5452.4050.4848.98(51.51)66.7654.80
EBITDA margin+12.2%+14.5%+15.2%+16.3%-18.5%+21.7%+19.6%
Profit before tax49.1044.1342.1336.32(63.38)56.7448.52
Net profit38.9942.6236.8935.1723.7955.6550.47
Net profit margin+9.0%+11.8%+11.1%+11.7%+8.6%+18.1%+18.0%
EPS (₹)23.3822.1721.1418.50(35.43)29.2926.56
Balance sheet
Total assets816763722681638717630
Net worth689649611573542613558
Total debt12211110810592.9510170.15
Cash & bank70.6787.6375.5037.984.1729.2221.98
Net working capital497427413409366463373
Cash flow
Cash from operations(13.91)26.8074.7238.3717.051.119.48
Cash from investing3.46(4.05)(27.40)(2.88)(19.87)(10.28)(14.44)
Cash from financing(6.51)(10.62)(9.81)(1.67)(22.23)16.405.56
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue32345.6965.9639.7728049.3736.8732.19
Revenue growth (YoY)+15.2%-7.5%+78.9%+23.6%+14.9%---
Other income3.103.634.421.933.834.580.480.07
Total expenses28839.0857.1332.5825046.2029.3625.63
EBITDA35.076.618.837.1929.903.177.516.56
EBITDA margin+10.9%+14.5%+13.4%+18.1%+10.7%+6.4%+20.4%+20.4%
Depreciation1.011.020.980.980.981.320.830.83
Interest3.792.944.183.302.891.103.372.94
Profit before tax33.376.288.094.8429.865.333.792.86
Tax0.722.500.870.640.660.631.14(0.03)

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 30 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue32851.5965.9643.8528451.9736.8732.19
Revenue growth (YoY)+15.8%-0.7%+78.9%+36.2%+16.3%---
Other income3.103.634.424.003.834.400.480.08
EBITDA35.154.473.576.1029.280.428.034.81
EBITDA margin+10.7%+8.7%+5.4%+13.9%+10.3%+0.8%+21.8%+14.9%
Depreciation1.011.030.980.990.981.340.830.83
Interest4.264.594.543.663.201.373.902.98
Profit before tax32.982.482.475.4528.932.113.781.08
Tax0.722.500.870.640.660.631.14(0.03)
Net profit32.26(0.02)1.604.8128.271.482.641.11
EPS (₹)16.98(0.79)0.892.5314.880.421.330.53
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2012-13
Revenue445365333301278138
Revenue growth+22.0%+9.7%+10.4%+8.3%--
Other income13.825.094.080.551.850.58
Total expenses393315283253330118
Employee cost0.0031.8327.5823.3224.7810.22
EBITDA52.4449.9649.9548.83(51.56)19.90
EBITDA margin+11.8%+13.7%+15.0%+16.2%-18.5%+14.5%
Depreciation3.963.823.263.013.084.51
Interest15.9910.659.2010.2110.643.67
Profit before tax46.3140.5841.5736.16(63.43)12.30
Tax4.671.981.951.153.950.55
Net profit36.2439.0736.3335.0323.7411.75
Net profit margin+8.1%+10.7%+10.9%+11.6%+8.5%+8.5%
EPS (₹)20.9820.3120.8518.43(35.46)7.34
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2012-13
Equity & liabilities
Share capital19.0019.0019.0019.0019.0016.00
Reserves & surplus66162559155452341.47
Shareholders' funds (net worth)68064461057354257.47
Minority interest0.000.000.00(0.02)0.000.00
Secured loans95.0610610310491.0714.75
Unsecured loans43.4416.256.951.031.884.44
Total debt13812311010592.9519.19
Total liabilities82477072368163778.13
Assets
Gross block27527927427026776.75
Net block24925024924424537.62
Capital work in progress0.020.000.000.000.000.00
Investments5.905.786.055.055.050.00
Inventories45133823020822077.17
Sundry debtors85.4188.9094.3197.3185.5520.99
Cash & bank balances76.0088.9077.4138.004.182.48
Loans & advances16717417017815819.11
Total current assets779690572521468120
Total current liabilities27425615711210280.15
Net working capital50543441540936639.60
Total assets82477072368163778.13
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2012-13
Opening cash88.9077.4138.004.1829.22-
Net cash from operating activities(12.57)17.5874.5938.3717.05-
Net cash from investing activities3.46(3.96)(27.40)(2.88)(19.85)-
Net cash from financing activities(3.79)(2.13)(7.78)(1.67)(22.23)-
Net change in cash(12.90)11.4939.4133.81(25.04)-
Closing cash76.0088.9077.4138.004.18-
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2012-13
Growth
Sales growth+22.0%+9.7%+10.4%+8.3%--
EBITDA growth+5.0%+0.0%+2.3%+194.7%--
PBT growth+14.1%-2.4%+15.0%+9998.0%-+9997.0%
Net income growth-7.2%+7.5%+3.7%+47.6%--
Revenue CAGR (3Y)+13.9%+9.4%+34.2%---
EBITDA CAGR (3Y)+2.4%-+35.9%---
Profitability & leverage
Net income margin+9.4%+10.6%+11.9%+11.6%-24.2%+8.5%
Return on capital employed-+6.9%+7.2%+7.0%+5.6%+23.4%
Return on net worth-+6.2%+6.7%+6.3%+4.4%+22.8%
Debt / equity-0.190.180.180.170.29
Long-term debt / equity-0.010.000.000.000.02
Interest cover32.9823.0819.7022.28-19.4723.85
Efficiency & per share
Fixed asset turnover-1.321.221.121.042.08
Inventory turnover-1.281.521.411.261.93
Debtors turnover-3.983.473.303.258.24
EPS (₹)20.9820.3120.8518.43(35.46)7.34
Dividend per share (₹)2.002.002.002.002.000.00
Book value per share (₹)0.00339.08320.94301.61285.1635.91
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue32345.6965.9639.7728049.3736.8732.19
Revenue growth (YoY)+15.2%-7.5%+78.9%+23.6%+14.9%---
Other income3.103.634.421.933.834.580.480.07
Total expenses28839.0857.1332.5825046.2029.3625.63
EBITDA35.076.618.837.1929.903.177.516.56
EBITDA margin+10.9%+14.5%+13.4%+18.1%+10.7%+6.4%+20.4%+20.4%
Depreciation1.011.020.980.980.981.320.830.83
Interest3.792.944.183.302.891.103.372.94
Profit before tax33.376.288.094.8429.865.333.792.86
Tax0.722.500.870.640.660.631.14(0.03)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue432362333301278308280
Revenue growth+19.1%+8.9%+10.4%+8.2%-9.5%+9.9%-
Other income13.825.274.100.561.851.671.82
Total expenses379310282252330241225
Employee cost0.0029.6427.3123.2324.7823.6918.74
EBITDA52.5452.4050.4848.98(51.51)66.7654.80
EBITDA margin+12.2%+14.5%+15.2%+16.3%-18.5%+21.7%+19.6%
Depreciation3.953.793.263.013.082.821.45
Interest13.319.759.1910.2110.648.876.65
Profit before tax49.1044.1342.1336.32(63.38)56.7448.52
Tax4.671.981.951.153.951.09(1.98)
Net profit38.9942.6236.8935.1723.7955.6550.47
Net profit margin+9.0%+11.8%+11.1%+11.7%+8.6%+18.1%+18.0%
EPS (₹)23.3822.1721.1418.50(35.43)29.2926.56
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital19.0019.0019.0019.0019.0019.0019.00
Reserves & surplus670630592554523594539
Shareholders' funds (net worth)689649611573542613558
Secured loans95.0610610310491.0788.6363.37
Unsecured loans26.674.884.911.031.8812.156.78
Total debt12211110810592.9510170.15
Total liabilities816763722681638717630
Assets
Gross block275279274270267267265
Net block249250249244245247246
Capital work in progress0.020.000.000.000.000.000.00
Investments6.176.056.065.065.065.055.00
Inventories445331229208220226204
Sundry debtors83.7988.8494.3197.3185.55109107
Cash & bank balances70.6787.6375.5037.984.1729.2221.98
Loans & advances165173170178158171139
Total current assets764681569521468536472
Total current liabilities26725415511210272.8799.77
Net working capital497427413409366463373
Total assets816763722681638717630
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash87.6375.5037.984.1729.2221.9821.38
Net cash from operating activities(13.91)26.8074.7238.3717.051.119.48
Net cash from investing activities3.46(4.05)(27.40)(2.88)(19.87)(10.28)(14.44)
Net cash from financing activities(6.51)(10.62)(9.81)(1.67)(22.23)16.405.56
Net change in cash(16.97)12.1337.5233.82(25.05)7.230.61
Closing cash70.6787.6375.5037.984.1729.2221.98
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+19.1%+8.9%+10.4%+8.2%-9.5%+9.9%-
EBITDA growth+0.3%+3.8%+3.1%+195.1%-177.2%+21.8%-
PBT growth+11.3%+4.8%+16.0%+9998.0%-+16.9%+24.9%
Net income growth-8.5%+15.5%+4.9%+47.8%-57.3%+10.3%-
Revenue CAGR (3Y)+12.7%+9.2%+2.7%+2.5%+6.4%+17.1%+18.1%
EBITDA CAGR (3Y)+2.4%--8.9%-3.7%-+18.2%+23.6%
Profitability & leverage
Net income margin+10.3%+11.6%+12.1%+11.7%-24.2%+18.1%+18.0%
Return on capital employed-+7.3%+7.3%+7.1%+5.3%+9.7%+9.2%
Return on net worth-+6.7%+6.8%+6.3%+4.1%+9.5%+9.5%
Debt / equity-0.170.180.180.170.150.12
Long-term debt / equity-0.000.000.00-7,615.540.000.00
Interest cover27.3920.0619.4622.21-19.4913.8712.46
Efficiency & per share
Fixed asset turnover-1.311.221.121.041.161.09
Inventory turnover-1.291.521.411.251.431.56
Debtors turnover-3.963.473.302.862.842.60
EPS (₹)23.3822.1721.1418.50(35.43)29.2926.56
Dividend per share (₹)2.002.002.002.002.002.000.00
Book value per share (₹)0.00341.33321.33301.70285.19322.71293.42

To see the full year-wise statements and ratios of Nath Bio-Genes (India) Limited, buy the company report.

Board of directors of Nath Bio-Genes (India) Limited

Nath Bio-Genes (India) has 7 current directors and 12 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Satish Laxminarayan KagliwalManaging Director29 Mar 200026 Years 7 MonthsCurrent
Madhukar Dhondiraj DeshpandeDirector10 Feb 20215 Years 8 MonthsCurrent
Jeevanlata Nandkishor KagliwalDirector30 May 20197 Years 5 MonthsCurrent
Hitesh Rajnikant PurohitDirector30 Mar 20224 Years 7 MonthsCurrent
Vadla NagabhushanamDirector07 Nov 20205 Years 11 MonthsCurrent
Payal Dilipkumar JainDirector11 Jul 20251 Years 3 MonthsCurrent
Showing 6 of 7 current directors. View all directors

Auditor

Nath Bio-Genes (India) Limited is audited by GAUTAM N ASSOCIATES for the financial year 2023.

Auditor firmFinancial yearFirm registration number
GAUTAM N ASSOCIATESFY 2023103117W

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 45.60%, foreign institutional investors hold 0.30%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 54.10%.

Promoters: 45.60%FII (Foreign Institutional): 0.30%Retail & Others: 54.10%
Sep 2026
QUARTER
45.60% Promoters
0.30% FII (Foreign Institutional)
54.10% Retail & Others
Promoter holding - history
Now 45.60% · Sep 2026High 45.60% · Dec 2025Low 45.60% · Dec 2025
44%44.8%45.5%46.3%47%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 45.60%Mar 2026: 45.60%Jun 2026: 45.60%Sep 2026: 45.60%45.60%45.60%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters45.60%45.60%45.60%45.60%
Public54.40%54.40%54.40%54.40%

Charges & borrowings

Open charges
₹114.1 Cr
Satisfied charges
₹183.2 Cr
Breakdown by lending institutions
Axis Bank Limited₹105.40 Cr
Others₹5.80 Cr
Hdfc Bank Limited₹2.90 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
30 Jul 2025101141509Others₹5 CrOpen
13 Jun 2025101139826Others₹80 LakhOpen
21 Jun 2024100940798Axis Bank Limited₹10.25 LakhOpen
03 Apr 2024100912748Hdfc Bank Limited₹57.78 LakhOpen
06 Mar 2024100886493Hdfc Bank Limited₹64.53 LakhOpen

To see the full charge records of Nath Bio-Genes (India) Limited, buy the company report.

Total charge records: 21 View all charges

Deals & funding

Nath Bio-Genes (India) Limited has 44 deals on record (43 market trades, 1 qip); the latest was in September 2025.

Total deals
44
Market trades
43
QIP
1

Deals on record (5 of 44)

WhenDealAmountParties
Jul 2024Market trade₹3.5 CrBuyer: Adroit Financial Services Private Limited
Seller: Adroit Financial Services Private Limited
Jul 2024Market trade₹5.19 CrBuyer: Jainam Broking Limited , Graviton Research Capital LLP
Seller: Graviton Research Capital LLP , Jainam Broking Limited
Feb 2024Market trade₹10.94 CrBuyer: Akash Farms LLP
Seller: Agri-Tech (India) Limited
Jan 2024Market trade₹4.76 CrBuyer: Bakulesh Shah Private Trust
Seller: KBS Properties Private Limited
Jan 2024Market trade₹4.49 CrBuyer: Graviton Research Capital LLP
Seller: Graviton Research Capital LLP

To see the full deal history of Nath Bio-Genes (India) Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

Credit ratings & regulatory alerts

Nath Bio-Genes (India) Limited was last rated by Crisil on 27 Sep 2021.

Rating agencyRated onRating
Crisil27 Sep 2021

To see the full credit ratings and regulatory alerts of Nath Bio-Genes (India) Limited, buy the company report.

MSME payment delays

No delayed payments to MSME suppliers are on our record for Nath Bio-Genes (India) Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.

Employees & EPFO

Nath Bio-Genes (India) Limited has a workforce of 417 employees on its EPFO records as of Apr 02, 2024, across 1 active EPFO establishment.

Employee count
417
Active EPFO establishments
1
Employee growth
-1.18%

GST

Nath Bio-Genes (India) has 15 GST registrations: 13 active and 2 cancelled or inactive. The first 4 active GSTINs are listed below.

Total GSTINs
15
Active
13
Cancelled / inactive
2
GSTINStateStatusRegistered on
03AABCN7978E1ZDPunjabActive01 Jul 2017
06AABCN7978E1Z7HaryanaActive01 Jul 2017
08AABCN7978E1Z3RajasthanActive01 Jul 2017
09AABCN7978E1Z1Uttar PradeshActive01 Jul 2017

To see the full GST registrations and return filing status of Nath Bio-Genes (India) Limited, buy the company report.

Recent activity

Nath Bio-Genes (India) Limited has 29 board changes on record since 2000: 18 appointments and 11 cessations. The latest: Payal Dilipkumar Jain was appointed as Director on 11 Jul 2025.

Filing
Nath Bio-Genes (India) Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Mumbai Ii.
AGM
Nath Bio-Genes (India) Limited last Annual general meeting of members was held on 22 Aug 2025 as per latest MCA records.
Charges
A charge with Others amounted to Rs. 5.00 Cr with Charge ID 101141509 was registered on 30 Jul 2025.
Appointed
Payal Dilipkumar Jain was appointed as Director.
Ceased
Shipra Atithi Agrawal ceased to be Additional Director.
Charges
A charge with Others amounted to Rs. 0.80 Cr with Charge ID 101139826 was registered on 13 Jun 2025.
Ceased
Ashu Jain ceased to be Director.
Appointed
Shipra Atithi Agrawal was appointed as Additional Director.
Ceased
Devinder Khurana ceased to be CFO.
Charges
A charge with Axis Bank Limited amounted to Rs. 0.10 Cr with Charge ID 100940798 was registered on 21 Jun 2024.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 0.58 Cr with Charge ID 100912748 was registered on 03 Apr 2024.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 0.65 Cr with Charge ID 100886493 was registered on 06 Mar 2024.

55 earlier events are in the company report.

Frequently asked questions

Nath Bio-Genes (India) is an active public limited company based in Aurangabad, Maharashtra, India. The company works in seed production and distribution, within the agriculture industry. It was incorporated on 14 July 1993 (33+ years old) and is registered under CIN L01110MH1993PLC072842. Listed on BSE: 537291 and NSE: NATHBIOGEN.

Nath Bio-Genes (India) reported revenue of ₹445.1 Cr for FY 2025-26 (up 22% YoY) based on consolidated financials.

Nath Bio-Genes (India) has 7 current directors:

The latest financial statements of Nath Bio-Genes (India) on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 22 August 2025. Year-wise statements from 2015 are in the company report.

The GSTIN of Nath Bio-Genes (India) is 03AABCN7978E1ZD, registered in Punjab. The company has 15 GST registrations in all, of which 13 are active and 2 are cancelled or inactive. Other active GSTINs include 06AABCN7978E1Z7 (Haryana), 08AABCN7978E1Z3 (Rajasthan), 09AABCN7978E1Z1 (Uttar Pradesh).

The CIN (Corporate Identification Number) of Nath Bio-Genes (India) is L01110MH1993PLC072842. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Nath Bio-Genes (India) is a listed company as per MCA records. Its shares are listed on both BSE (code: 537291) and NSE (symbol: NATHBIOGEN).

Nath Bio-Genes (India) has 34 court cases on record: 18 filed by the company and 16 filed against it. 14 are pending. Most are in the district courts.

Nath Bio-Genes (India) was incorporated on 14 July 1993, making it 33+ years old. It is registered with the Registrar of Companies, Mumbai.

Nath Bio-Genes (India) has 44 deals on record (43 market trades, 1 qip); the latest was in September 2025.